Christopher Baum mostly deals with Gene, Genetic enhancement, Transgene, Virology and Genetics. His Gene study frequently draws connections between related disciplines such as Cell biology. His Genetic enhancement study combines topics from a wide range of disciplines, such as Molecular biology, Leukemia, Severe combined immunodeficiency and Transfection.
In his study, Bioinformatics is strongly linked to Hematopoietic stem cell transplantation, which falls under the umbrella field of Transgene. His study connects Viral vector and Virology. Christopher Baum works mostly in the field of Genetics, limiting it down to concerns involving Computational biology and, occasionally, Biosafety and Somatic cell.
His main research concerns Genetic enhancement, Haematopoiesis, Molecular biology, Stem cell and Viral vector. His studies deal with areas such as Transgene, Vector and Immunology as well as Genetic enhancement. His research in Haematopoiesis intersects with topics in Progenitor cell, CD34, Cancer research and Bone marrow.
His Molecular biology study deals with Long terminal repeat intersecting with Enhancer. His study in Stem cell is interdisciplinary in nature, drawing from both In vivo and Transplantation. The various areas that Christopher Baum examines in his Viral vector study include Transduction, splice and Virology.
Christopher Baum spends much of his time researching Haematopoiesis, Genetic enhancement, Cell biology, Molecular biology and Immunology. Christopher Baum combines subjects such as CD34, Cancer research and Bone marrow with his study of Haematopoiesis. His Genetic enhancement research includes themes of Viral vector, Severe combined immunodeficiency and Transduction.
His Viral vector research is multidisciplinary, incorporating perspectives in Gene expression profiling and Virology. As part of one scientific family, Christopher Baum deals mainly with the area of Molecular biology, narrowing it down to issues related to the Transgene, and often Exon. His work deals with themes such as Hematopoietic stem cell transplantation and Transplantation, which intersect with Immunology.
Christopher Baum mostly deals with Haematopoiesis, Immunology, Virology, Genetic enhancement and Genetics. The study incorporates disciplines such as Transduction and Bone marrow in addition to Haematopoiesis. His work on Leukemia as part of general Immunology research is frequently linked to Diamond–Blackfan anemia, thereby connecting diverse disciplines of science.
His Virology research is multidisciplinary, incorporating elements of Progenitor cell, Viral vector and Transplantation. Genetic enhancement is a subfield of Gene that he investigates. His work in Genetics addresses issues such as Computational biology, which are connected to fields such as Biosafety and Pseudotyping.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Murine leukemia induced by retroviral gene marking.
Zhixiong Li;Zhixiong Li;Jochen Düllmann;Bernd Schiedlmeier;Manfred Schmidt.
Side effects of retroviral gene transfer into hematopoietic stem cells
Christopher Baum;Jochen Düllmann;Zhixiong Li;Boris Fehse.
Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors
Ute Modlich;Susana Navarro;Daniela Zychlinski;Tobias Maetzig.
Molecular Therapy (2009)
Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.
Christopher Baum;Olga Kustikova;Ute Modlich;Zhixiong Li.
Human Gene Therapy (2006)
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Salima Hacein-Bey-Abina;Sung Yun Pai;H. Bobby Gaspar;Myriam Armant.
The New England Journal of Medicine (2014)
Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking
Olga Kustikova;Boris Fehse;Ute Modlich;Min Yang.
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Ute Modlich;Jens Bohne;Manfred Schmidt;Christof von Kalle.
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells.
C Baum;S Hegewisch-Becker;H G Eckert;C Stocking.
Journal of Virology (1995)
Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
Daniela Zychlinski;Axel Schambach;Ute Modlich;Tobias Maetzig.
Molecular Therapy (2008)
Chance or necessity? Insertional mutagenesis in gene therapy and its consequences
Christopher Baum;Christof von Kalle;Frank J.T Staal;Zhixiong Li.
Molecular Therapy (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: